Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming ...

Evercore 8th Annual Healthcare Conference December 3, 2025 10:00 AM ESTCompany ParticipantsPeter Griffith - Executive VP & ...

India-based firm Lupin has joined the pegfilgrastim parade with the FDA’s approval of Armlupeg (pegfilgrastim-unne), the seventh biosimilar for Amgen’s Neulasta approved in the US since 2018.

With notable therapies from Biogen, Sarepta and MacroGenics failing to show efficacy in pivotal or confirmatory trials, experts question the use of biomarker evidence for approval while one former ...

Amgen’s AMGN stock has risen almost 16% in a month. A lot of this price increase is due to strong third-quarter 2025 results, wherein both the top and bottom lines exceeded expectations. Amgen also ...

Some younger patients with B-cell acute lymphoblastic leukemia may be able to avoid total body irradiation conditioning prior ...

Rory McIlroy completed the Grand Slam in 2025 by winning The Masters at Augusta National and claiming elusive fifth major; McIlroy also won the Ryder Cup with Team Europe at Bethpage Black before secu ...

Once largely a diagnosis of exclusion, new tools and treatments are unraveling some of the mysteries surrounding heart failure with preserved ejection fraction.

As of Monday, December 08, TScan Therapeutics, Inc.’s TCRX share price has dipped by 13.80%, which has investors questioning if this is right time to buy.

What's really holding America back in the biopharma race against China isn't just Beijing's subsidies or cheaper labor. It's ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Nurix Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The era of AI agents,” as Microsoft claimed at its recent Build 2025 conference, was meant to mark a new era of self-driven ...